Concepedia

Yang Ou

YO

Statistics

Publications

9

Citations

319

H-Index

9

Active since

2008

Affiliations

Eli Lilly (United States)(Current)

University of Virginia

Mayo Clinic in Arizona

Merck & Co., Inc., Rahway, NJ, USA (United States)

University of Virginia Health System

Yang Ou is an author at Eli Lilly (United States) specializing in medicine, tumor biology, and pathology.

ORCID

Top concepts

Publications per year

2008–2025

9

Publications

9

Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure

Christopher M. Kramer, Barry A. Borlaug, Michael R Zile M et al. · Journal of the American College of Cardiology · 2024 · 111 citations · Full text

Randomized, placebo-controlled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC).

Yang Ou, M. Dror Michaelson, L. Sengeløv et al. · Journal of Clinical Oncology · 2011 · 56 citations

Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Michael R. Zile, Barry A. Borlaug, Christopher M. Kramer et al. · Circulation · 2024 · 37 citations · Full text

[alpha1,2-fucosyltransferase gene transfection influences on biological behavior of ovarian carcinoma-derived RMG-I cells].

Ying Hao, Bei Lin, Yue Zhao et al. · PubMed · 2008 · 24 citations

, , +14

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity

Milton Packer, Michael R. Zile, Christopher M. Kramer et al. · Journal of the American College of Cardiology · 2025 · 24 citations

1–5 of 9